Fundz

Santa Ana Bio raised $168 million in combined Series A and B funding led by GV and Versant Ventures

PRIVATEJun 14, 2024

Amount Raised

$168 Million

Round Type

Series B

AlamedaBiotechnology

Investors

Andreessen Horowitz (A16z) BioAccess BiotechnologyGVTpg’s Life Science Innovations FundVersant Ventures

Description

US precision immunology company Santa Ana Bio emerged from stealth with $168 million in combined Series A and B funding. Versant Ventures led the Series A round and GV led the $125 million Series B round.

Quick answer

Santa Ana Bio raised $168 Million in a Series B round, dated June 14, 2024. Investors: Andreessen Horowitz (A16z) Bio, Access Biotechnology, GV, Tpg’s Life Science Innovations Fund and Versant Ventures. Santa Ana Bio is based in Alameda, California, United States.

How much did Santa Ana Bio raise?
Santa Ana Bio raised $168 Million in a Series B round on June 14, 2024.
Who invested in Santa Ana Bio?
Andreessen Horowitz (A16z) Bio, Access Biotechnology, GV, Tpg’s Life Science Innovations Fund and Versant Ventures are named as investors in this round.
What does Santa Ana Bio do?
Santa Ana Bio is a Bay Area biotech focused on leveraging it’s multiomics and protein engineering platforms to design precision biologics for the treatment of patients with serious immune related diseases.
Where is Santa Ana Bio based and how big is it?
Santa Ana Bio is based in Alameda, California, United States.
Who are the decision-makers at Santa Ana Bio?
Fundz holds 1 contact at Santa Ana Bio, including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Santa Ana Bio that raised within 45 days of this round, from Fundz verified event records.

  • Melt&Marble raised $3M (Funding Round) on July 29, 2024.
  • Chemomab Therapeutics Ltd raised $10M on July 29, 2024.
  • Schrodinger, Inc. raised $10M (Grant) on July 29, 2024.
  • Spear Bio raised $45M (Series A) on July 29, 2024.
  • CEL-SCI Corporation raised $11M (Debt Financing) on July 29, 2024.
  • LinusBio raised $6.1M on July 29, 2024.

Who to call at Santa Ana Bio, and when

A new round usually means Santa Ana Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Santa Ana Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Santa Ana Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Santa Ana Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Santa Ana Bio

Location

1105 Atlantic Avenue

Alameda, California, United States

About

Santa Ana Bio is a Bay Area biotech focused on leveraging it’s multiomics and protein engineering platforms to design precision biologics for the treatment of patients with serious immune related diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Santa Ana Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsPeter E., Executive Officer, Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Santa Ana Bio's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Santa Ana Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.